China’s CMAB Biopharma captures $34M in series B funding to upgrade facilities

Suzhou, China
The company said it will use the funds to upgrade its plant in the Suzhou BioBay Park in China. (Christian Gänshirt/CC BY-SA 4.0)

CMAB Biopharma, a China-based CDMO, snagged $34 million in series B financing the company said will be used to upgrade and expand its manufacturing plant.

The company, which specializes in the development and manufacturing of biologics products, said it will use the funds to upgrade its plant in the Suzhou BioBay Park in China. 

The funding round was led by CD Capital, with joint participation by C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed.

“We aim to bring our client expertise and knowledge to efficiently advance products from concept into the clinic,” Qibin Liang, CMAB’s president, said in a statement. “This financing furthers our vision to become a fully integrated CDMO platform providing clinical and commercial production services to the Chinese domestic and the international biologics markets.”

The company said its manufacturing facility will be able to generate preclinical and early-stage clinical (phase 1/2) products using manufacturing that follows global GMP standards.


Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.